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Purpose: To identify the prevalence of potential drug-drug interactions (pDDIs) in a psychiatric ward, their 
levels and association with risk factors.  
Methods: This study was conducted in the psychiatric ward of Ayub Teaching Hospital, Abbottabad, Pakistan. 
Medical records of 415 patients were retrospectively reviewed for pDDIs using Micromedex Drug-Reax 
software. Logistic regression was applied to determine association of pDDIs with age, gender, hospital stay 
and number of drugs.  
Results: In our study, we identified total number of 825 pDDIs of 126 types, with median number of 1 pDDIs 
per patient. Overall 64.8 % of the patients had at least one pDDI; 27.2 % at least one major pDDI; and 58.5 % 
patients at least one moderate pDDI. Among 825 identified pDDIs, most were of moderate (75.6 %) or major 
(20.8 %) severity, good (66.4 %) or fair (29 %) type of scientific evidence; and delayed onset (71 %). The most 
frequent major and moderate pDDIs included haloperidol + procyclidine (127 cases), haloperidol + olanzapine 
(49), haloperidol + promethazine (47), haloperidol + fluphenazine (41), diazepam + divalproex sodium  (40), 
haloperidol + trihexyphenidyl (37), lorazepam + divalproex sodium (34), fluphenazine + procyclidine (33) and 
olanzapine + divalproex  sodium (32). There was significant association of occurrence of pDDIs with hospital 
stay of 7 days or longer (p = 0.005) and taking 7 or more drugs (p < 0.001). 
Conclusion: A high prevalence of pDDIs in the psychiatric ward was recorded, a majority of which were of 
moderate severity. Patients with long hospital stay and increased number of drugs were more exposed to 
pDDIs.  
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INTRODUCTION 
 
Drug-drug interactions (DDIs) can lead to 
alteration of therapeutic response or increase 
untoward effects of many drugs [1]. The issue 
of DDIs needs more attention in the case of 
hospitalized patients due to severity of 
disease, polypharmacy, co-morbid 
conditions, chronic diseases, complex 
therapeutic regime, and frequent modification 
in therapy [2]. Prevalence of potential DDIs 
(pDDIs) in hospital settings has been 
estimated in some recent studies to be in the 
range of 27.8 to 51.4 % [2-4]. Old age, taking 
increased number of medications, long 
hospital stay, gender and comorbid 
conditions have been reported as common 
risk factors for DDIs [5-11]. 
 
In comparison to other clinical specialty 
wards, e.g., internal medicine wards 
[4,12,13], very few studies have addressed 
the issue of DDIs in psychiatric wards. A 
small scale cross-sectional survey (n = 48), 
conducted in elderly psychiatric wards 
identified a total of 152 pDDIs in 96 % (46/48) 
of prescriptions [14]. Davies et al evaluated 
323 prescriptions of adult and elderly patients 
of psychiatric wards in England for pDDIs 
involving two isoforms of cytochrome P450, 
CYP2D6 and CYP3A4. Eighty two CYP2D6-
combinations in 62 patients (19 %) and 24 
CYP3A4-combinations in 20 patients (6 %) 
were reported to be clinically important or 
potentially clinically important [15]. In a 
similar study (n = 323) conducted in 
psychiatric wards in England to assess 
prevalence of PRN (pro re nata, i.e., as 
required) drug prescriptions and potential for 
interactions involving CYP2D6 and CYP3A4, 
it was found that 20 % of the patients were 
prescribed drug combinations interacting with 
CYP2D6 or CYP3A4 which included one or 
more drugs prescribed on a PRN basis [16]. 
Studies are needed to explore the overall 
pattern of pDDIs in psychiatric wards along 
with their levels and correlation with different 
risk factors. 
 
The primary aim of our study was to identify 
the prevalence of pDDIs in prescriptions of 
hospitalized patients in a psychiatric ward in 
a Pakistani tertiary care hospital, their levels, 
and association with specific potential risk 
factors such as age, gender, hospital stay 
and number of drugs. A secondary aim was 
to report commonly occurring interacting 






This study was conducted in the psychiatric 
ward of Ayub Teaching Hospital (ATH), 
Abbottabad, KPK, Pakistan, which is a 1000-
bed tertiary care teaching hospital. ATH 
provides health care and referral services to 
a population of more than 400,000 
inhabitants in Abbottabad and several 
northern areas of Pakistan, including 
Mansehra, Kohistan and Azad Jammu and 
Kashmir (AJK).  
 
Design and study population 
 
This was a retrospective cross-sectional 
study carried out using medical records of 
patients admitted to the psychiatric ward 
during a 1-year period from 1st September 
2008 to 31st August 2009. Patients’ records 
with incomplete information were excluded 
from the study. This study was approved by 
the Ethical Committee of the Department of 




Permission was obtained from hospital 
administration to use patients’ medical 
records for the collection and analysis of 
prescription data. The records were 
retrospectively reviewed and the following 
data were collected: patient’s age, gender, 
duration of hospital stay, and names and 
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Screening of pDDIs 
 
All medications that were prescribed to the 
patients during the entire hospital stay, i.e., 
from the date of admission until discharge, 
and these included routine and PRN 
medications, were screened for pDDIs. 
Micromedex Drug-Reax® System  (Thomson 
Reuters Healthcare Inc., Greenwood Village, 
Colorado, USA) was used to screen and 
classify pDDIs [17]. PDDIs were categorized 
into different levels as follows. 
 
Onset 
• Rapid: The effect of interaction occurs 
within 24 hours of administration.  
• Delayed: The effect occurs if the 
interacting combination is administered 
for more than 24 h, i.e., days to week(s). 
 
Severity  
• Contraindicated: The drug-combination is 
contraindicated for concurrent use. 
• Major: There is risk of death and/or 
medical intervention is required to 
prevent or minimize serious negative 
outcomes. 
• Moderate: The effect of interaction can 
deteriorate patient’s condition and may 
require alteration of therapy. 
• Minor: Little effects are produced that 
don’t impair therapeutic outcome and 
there is no need of any major change in 
therapy. 
 
Scientific evidence (Documentation) 
• Excellent: The interaction has been 
clearly demonstrated in well-controlled 
studies. 
• Good: Studies strongly suggest that the 
interaction exists except proof of well-
controlled studies. 
• Fair: Available evidences are poor, but 
the interaction is suspected on the basis 
of pharmacologic considerations; or, 
evidences are good for an interaction of 
pharmacologically similar drug. 
• Poor: Theoretically the interaction may 
occur but reports are very limited, such 
as few case reports. 
• Unlikely: Data are very poor and lack a 




The results are presented as median, range 
and proportion where appropriate. Logistic 
regression was applied to determine the odds 
ratio for different risk factors, i.e., age, 
gender, hospital stay and number of drugs. 
The presence of pDDI(s) was the dependent 
variable in the model (0 = absent, 1 = 
present). The following variables were 
included in the model as predictors of pDDIs: 
patient’s age (1 = below 46 years, 2 = ≥ 46 
years), gender (1 = female, 2 = male), 
hospital stay (1 = < 7 days, 2 = ≥ 7 days), and 
number of drugs (1 = < 7, 2 = ≥ 7). “Enter” 
method was used for analysis. Hosmer–
Lemeshow test was used to evaluate 
goodness-of-fit of the model. P-value of 0.05 
or less was considered statistically 
significant. SPSS for Windows version 16 
(SPSS, Inc., Chicago, IL, USA) was used for 




General patient characteristics  
 
Of the total of 427 patients’ medical records, 
12 were excluded due to incomplete 
information, while 415 were reviewed for 
pDDIs. In the study, among the 415 patients, 
195 (47 %) were male and 220 (53 %) 
female; median age was 25 years; median 
hospital stay 5 days and median number of 
prescribed medications 5 (Table 1). 
 
Prevalence of pDDIs 
 
Table 2 shows that 269 (64.8 %) patients had 
at least one pDDI regardless of type of 
severity; 113 (27.2 %) and 243 (58.5 %) 
patients had at least one pDDI of major and 
moderate severity, respectively. Contra-
indications and minor types of pDDIs were 
least prevalent. In a majority cases, 1 - 2 
pDDIs per patients were identified with a 
median of 1 pDDI. A total number of 825 
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pDDIs and 126 types of interacting 
combinations were identified. 
 
Table 1: General patient characteristics 
 





Age  (years)  
≤ 14 
15 - 30  
31 - 45 










8 – 100 yr 
Hospital stay (days)  
≤ 3 








1 – 20 days 
No. of prescribed medi-
cations per patient 
 
≤ 4 











Table 2: Prevalence of potential drug-drug 
interactions (pDDIs) 
 
Prevalence with  
respect to severity 






269 (64.8)  
    4 (01) 
113 (27.2) 
243 (58.5) 
 25 (06) 
Number of pDDIs  
per patient 





 77 (18.6) 
 41 (10) 






Levels of pDDIs 
 
The identified pDDIs were categorized into 
different levels according to onset, severity 
and scientific evidence. Table 3 shows these 
levels for all the pDDIs and 126 types of 
interacting combinations. Among the 825 
pDDIs, most were of moderate (624; 75.6 %) 
or major severity (172; 20.8 %); good (548; 
66.4 %) or fair (239; 29 %) type of scientific 
evidence; and delayed onset (586; 71%). A 
similar pattern was recorded for the 126 
types of interacting combinations (Table 3). 
 
Table 3: Levels of the identified potential drug-




(n = 825)  
Frequency 
of pDDIs 
type (n = 
126) 
Level 
n (%) n (%) 































Common interacting combinations 
 
In the study, we identified a total 126 types of 
interacting combinations. Common combi-
nations along with their frequencies are 
shown in Table 4. The top 20 commonly 
occurring pDDIs include 5 major, 14 
moderate and 1 minor pDDIs.  Haloperidol, 
procyclidine, fluphenazine, promethazine, 
olanzapine, trihexyphenidyl, fluoxetine, 
chlorpromazine, divalproex sodium, 
diazepam and lorazepam were the drugs 
most commonly encountered in these pDDIs.  
 
Association with potential risk factors 
 
Table 5 shows that, based on univariate 
analysis, there was significant association of  
the occurrence of one or more pDDIs with 
hospital stay of 7 days or longer (p < 0.001) ; 
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taking 7 or more drugs (p < 0.001)  and male 
gender (p = 0.04). In multivariate analysis, 
association was significant only in the case of 
hospital stay of 7 days or longer (p = 0.005) 
and taking 7 or more drugs (p < 0.001).  
 
Table 4: Common interacting drug-combinations 
 
Interaction Frequency 
Contraindicated   
Trifluoperazine + venlafaxine  2 
Major   
Haloperidol + promethazine 47 
Haloperidol + fluphenazine 41 
Haloperidol + chlorpromazine 14 
Haloperidol + lithium 8 
Propranolol + haloperidol 7 
Fluphenazine + lithium 6 
Imipramine + haloperidol; 
Diclofenac sodium + sertraline; 
Haloperidol + fluoxetine; 
Ibuprofen + sertraline; 
Imipramine + fluoxetine; 
Amitriptylline + haloperidol; 
Diclofenac sodium + 
escitalopram; Fluoxetine + 
trazodone; Imipramine + 
sertraline; Venlafaxine + 
tramadol; Venlafaxine + 
trazodone 
≤ 5 
Moderate   
Haloperidol + procyclidine 127 
Haloperidol + olanzapine 49 
Diazepam + divalproex  sodium 40 
Haloperidol + trihexyphenidyl 37 
Lorazepam + divalproex  sodium 34 
Fluphenazine + procyclidine 33 
Olanzapine + divalproex  sodium 32 
Promethazine + procyclidine 29 
Promethazine + trihexyphenidyl 25 
Trifluoperazine + procyclidine 17 
Alprazolam + fluoxetine; 
Divalproex sodium + risperidone 
13 each 




Minor   
Diazepam + fluoxetine 13 
Clonazepam + omeprazole; 
Diazepam + omeprazole; 
Propranolol + ciprofloxacin; 






The results of our study show that the 
prevalence of pDDIs in the psychiatric ward 
(64.8%) was higher compared to other 
hospitalized patients (49.7 % [3] and 27.8 % 
[2]) or patients of other wards such as 
internal medicine wards (51 % [4] and 60 % 
[13] ) and oncology wards (63 % [5]). In our 
study, prevalence of pDDIs of major severity 
(27.2 %) was also higher compared to other 
studies. Vonbach et al reported pDDIs of 
major severity in 3.1 % patients [12] while in 
another study Cruciol-Souza and Thomson 
estimated prevalence rate of 3.4 % for pDDIs 
of major severity [3]. We recorded average 
1.98 and median number of 1 pDDI per 
patient in our study. Average 1.44 pDDIs per 
patient was reported by Fokter et al [4] and 
median pDDIs of 2 per patient was estimated 
by Egger et al [13]. Vasudev and Harrison 
demonstrated a high prevalence of pDDIs (96 
%) in psychiatric wards [14]; Janchawee et al 
reported the highest prevalence of pDDIs in 
psychiatric prescriptions (57.8 %) compared 
to internal medicine (42.4 %), pediatrics (13.1 
%) and surgery (23.3 %) [18]. Both of above 
studies support our results, but partially, 
because study of Vasudev and Harrison 
included a small number (n = 48) of elderly 
patients only while Janchawee et al carried 
out their study on prescriptoin data of 
outpatient department of a university hospital. 
We can conclude that prevalence of pDDIs 
was higher in psychiatric ward as compared 
to other wards but further studies are needed.  
 
Moreover, this difference in prevalence may 
also be a result of high utilization of drugs 
having more interacting potentials (e.g., 
haloperidol, procyclidine, fluphenazine, 
promethazine, olanzapine, trihexyphenidyl, 
diazepam and lorazepam), absence of 
clinical pharmacist and/or drug information 
services by specialists (as in the case of the 
hospital studied), sensitivity of the source 
used for the screening of drug interactions 
and methodological design of the study. 
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Table 5: Logistic regression analysis* 
* Hosmer–Lemeshow goodness-of-fit test: p = 0.77  
**OR = Odds ratio;  CI = Confidence interval 
 
Many drug interactions compendia have 
assigned different levels or grades to drug 
interactions based on their severity, onset, 
evidences in scientific literature [17,19,20]. 
Importance of such grading can not be 
ignored in clinical practice. All pDDIs are not 
equally harmful, therefore, identification of 
levels for each pDDI is integral to assessing 
clinical importance and appropriate 
management. For this purpose, we 
categorized all identified pDDIs into different 
levels. Our findings regarding the levels of 
pDDIs are consistent with other studies [3-
5,13]. In our study, the major and moderate 
severity as well as good and fair 
documentation, identified for majority of 
pDDIs are of special concern. These findings 
indicate that the identified pDDIs have high 
potential to deteriorate patients’ clinical 
condition or to alter therapeutic response. 
Consequently, careful monitoring will be 
needed. 
 
The list in Table 4 should help physicians and 
clinical pharmacists to manage and prevent 
DDIs in psychiatric wards. The top 10 pDDIs 
are of special concern for practitioners as 
these interactions were of most common in 
our study. Divalproex sodium may increase 
the plasma levels of lorazepam and 
diazepam and can lead to toxicity including 
excessive sedation and respiratory 
depression. The patient should be monitored 
for evidence of such toxicity and dose should 
be adjusted accordingly. Concurrent use of 
haloperidol with promethazine or 
fluphenazine may result in an increased risk 
of cardiotoxicity including QT prolongation, 
torsade de pointes and cardiac arrest. Such 
combinations are better avoided, and if used, 
then close monitoring is required especially 
when starting, stopping or changing the dose 
of any interacting drug. Procyclidine may 
result in decreased serum-concentrations 
and effectiveness of phenothiazines 
(promethazine and fluphenazine) and 
enhanced anticholinergic effects including 
ileus, hyperpyrexia, sedation and dry mouth. 
Procyclidine and other anticholinergics 
(benztropine, orphenadrine and 
trihexyphenidyl) should not be used routinely 
with phenothiazine derivatives as prophylaxis 
against possible extrapyramidal symptoms. 
Their use should be reserved for those cases 
where reduction of the antipsychotic dosage 
is not possible. Anticholinergic use should be 
re-evaluated at least every three months.  
 
Combination of haloperidol with olanzapine 
may lead to increased risk of Parkinsonism 
and the adverse effect may include 
cogwheeling rigidity and unstable gait. 
Variable Patients, n (%) Univariate Multivariate 
 Interaction 
present 
(n = 269 ) 
Interaction 
absent 
(n = 146 ) 
OR** (95% CI**) P-
value 
OR** (95% CI) P-
value 
Patient age (year) 
< 46  



























1.48 (0.96-2.28) 0.072 
Hospital stay (day) 
< 7  












2.02 (1.24-3.28) 0.005 














3.37 (2.05-5.54) <0.001 
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Patients should be closely monitored for such 
adverse effects especially when olanzapine is 
added to haloperidol therapy. Haloperidol 
dosage may need to be decreased. Use of 
haloperidol with procyclidine or 
trihexyphenidyl may result in excessive 
anticholinergic effects including sedation, 
constipation and dry mouth. This combination 
should only be used when clearly indicated. 
Therapy should be closely monitored for 
excessive anticholineorgic effects and 
dosage may need to be adjusted. 
Combination of divalproex sodium with 
olanzapine may result in decreased 
olanzapine plasma concentrations. 
Therefore, plasma concentration of 
olanzapine should be monitored to ensure 
optimum response. Moreover, combination of 
divalproex sodium with olanzapine appears to 
increase the risk of hepatic injury. The 
authors of this report recommend monitoring 
of hepatic enzymes every 3 to 4 months for 
the first year of concurrent therapy, and then 
every 6 months if no adverse effects are 
detected [1,17,19,20]. 
 
Our findings regarding strong association of 
pDDIs with long hospital stay and taking 
increased number of drugs; and insignificant 
association with gender are consistent with 
other studies [5,6,8,9]. According to our 
findings, there was no significant relationship 
between old age and pDDIs that is 
inconsistent with other studies [5,7-10]. The 
possible reason for this inconsistency might 
be the small proportion of old age patients in 
our study population, i.e., 41(10 %) patients 
were of age 46 - 60 years and only 7(2 %) 
patients were older than 60 years (Table 1). 
 
Limitations of the study 
 
Potential limitations of this study include the 
following. The actual effects of the identified 
pDDIs were not evaluated. Studies are 
needed to identify actual clinical 
consequences of these interactions. The 
study population included a very small 
proportion of aged patients and the results 
might not have explored the pattern of pDDIs 
in these patients. Similar or higher 
prevalence rate of pDDIs in elderly 
psychiatric patients might be anticipated as 
evident from the survey of Vasudev and 
Harrison [14]. This study was carried out in a 
single institution and so its external validity is 
not known exactly and multicenter studies are 
therefore recommended. Micromedex Drug-
Reax® System [17] was used for screening 
of pDDIs in this study while other screening 





A high prevalence of pDDIs was recorded in 
the psychiatric ward studied, a majority of 
which were of moderate severity. Patients 
with long hospital stay and increased number 
of drugs were more exposed to pDDIs. 
Careful monitoring will be needed to manage 
and prevent negative clinical consequences 
of these interactions. Studies should be 
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